Cancer pharmacoepidemiology aims to reduce cancer incidence and mortality by identifying new drugs with potential to influence cancer outcomes, in particular, drugs less frequently prescribed or cancers with lower incidence.
We have established a European Cancer Pharmacoepidemiology network (E-CaPe) with access to national population based cancer registry datasets linked to prescribing data. The group unites and co-ordinates research activities across Europe, building capacity and expertise to undertake studies, and facilitates competitive collaborative applications for future research funding.
Primary membership is open to people working in this field within Europe. For more information see our membership page.